LONG MINI-FUTURE - NOVO-NORDISK B | Market Closed - Börse Stuttgart 11:41:23 30/04/2024 am IST | ||
| 20.37 EUR | -0.44% |
|
| Current month | -1.02% | ||
| 1 month | -1.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 20.37 | -0.44% | 0 |
| 29/24/29 | 20.46 | +1.99% | 0 |
| 26/24/26 | 20.06 | -0.20% | 0 |
| 25/24/25 | 20.1 | -2.57% | 0 |
| 24/24/24 | 20.63 | +2.28% | 0 |
Delayed Quote Börse Stuttgart
Last update April 30, 2024 at 11:41 am IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VL3HD3 |
| ISIN | DE000VL3HD37 |
| Date issued | 31/07/2017 |
| Strike | 121.2 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.94 € |
|---|---|
| Lowest since issue | 0.23 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
902.6
DKK
Average target price
904.2
DKK
Spread / Average Target
+0.18%
- Stock Market
- Certificates
- Certificat
